Journal article

The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma

Surein Arulananda, Erinna F Lee, W Douglas Fairlie, Thomas John

Expert Review of Anticancer Therapy | TAYLOR & FRANCIS LTD | Published : 2020


Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics  targeting them are a novel treatment option across various cancers, though have not been widel..

View full abstract


Awarded by National Health and Medical Research Council of Australia

Awarded by Australian Research Council

Awarded by Victorian Cancer Agency

Funding Acknowledgements

Support for this work was provided by a National Health and Medical Research Council of Australia Project Grant (GNT1157551) to W.D.F. and T. J. S.A. is the recipient of a La Trobe University Post Graduate Research Scholarship and a Lung Foundation Australia Grant-in-Aid. E.F.L. is a recipient of fellowships from the Australian Research Council (Future Fellowship FT150100212) and the Victorian Cancer Agency (Mid-Career Fellowship MCRF19045).